FemTech Accelerators and Incubators Accepting Applications
Most general health accelerators treat "women's health" like a subcategory they'll circle back to eventually. Femtech-specific programs skip that queue entirely. They build around the clinical, regulatory, and commercial quirks of the space from day one, because a menopause diagnostic and a maternal health platform don't share a regulatory pathway, a reimbursement model, or even a sales cycle. Stick both founders in the same generalist cohort and the mentor pool can't give either one advice sharp enough to actually use.
So what separates a real program from a logo on a website? Start with vertical specificity: does the accelerator's thesis actually line up with your sub-sector, whether that's reproductive health, cardiovascular disease, autoimmune conditions, or menopause? Stage fit trips up more founders than it should, too. Show up to a Series A program with a pre-seed deck and you've burned an application cycle for nothing.
Geography matters as well. North America still leads the global femtech market, holding 54.40% of the industry as of 2025 per Fortune Business Insights, but Southeast Asia has built its own dedicated infrastructure and turned into a genuinely high-growth region (more on that in the Inno4Her section below). Network composition tells you more than any homepage will: who the investors and corporate partners actually are, and what happened to last year's cohort once the program ended. Then there's dilution. Some programs take equity, some don't, and since VC investment in women's health makes up only about 4% of total healthcare VC according to VentureWell, a non-dilutive grant can be the smarter first move rather than a fallback plan.
More of the people running these programs now coach founders to lead their pitch with market economics, not the "women's health" label by itself. The category is real, sure, but investors fund total addressable markets, not mission statements. Say "this is a $10 billion market growing at double digits" and follow it with "this is underserved," and you've got a pitch. Say only the second half, and you've got an incomplete case.
Springboard Enterprises Women's Health Accelerator: 2027 waitlist open
Springboard has run since 2000, predating the term "accelerator" as most founders use it now. The track record holds up under scrutiny too: over 950 portfolio companies, more than $76 billion in value created, and 225 exits to strategic acquirers. Those are numbers a founder can go check, not numbers you have to take on faith.
The 2026 cohort brought in 11 companies across reproductive health, fertility, maternal health, diagnostics, therapeutics, and medical devices. By June 2026, the program had benefited over 65 women-led companies in total. Founders get workshops, one-on-one mentorship, strategic partnership introductions, and connections into growth capital, which tracks with who this program actually serves: later-stage companies, not someone still validating an early idea.
Read the eligibility bar closely before you apply, because it's specific. Springboard wants a woman in senior leadership, and it targets later-stage companies, so a pre-revenue idea won't fit here no matter how good the deck looks. Focus areas span a range of conditions relevant to women's health across the lifespan. The 2026 cohort got announced in March 2026, so the live window right now is the 2027 waitlist. Get on it at sb.co/programs/womens-health-accelerator-program.
FemTech Lab Global Accelerator: applications opening Autumn 2026
FemTech Lab runs a genuinely global operation: a community built since 2019 and an accelerator arm that has backed a growing number of startups. What sets it apart is speed. Early-stage companies per cohort, a focused sprint format, faster than most programs on this list ever bother to move.
Scope here runs wider than Springboard's, deliberately so. FemTech Lab takes any product improving women's health: conditions specific to women, conditions that hit women differently than men, conditions that hit women harder. That breadth lowers the bar for "fit," though it also means a bigger pool competing for the same ten slots.
The application itself moves fast. The application is designed to move quickly, with a review process and then an interview for qualifying founders to check mutual fit. Next cycle opens Autumn 2026, so join the waitlist now instead of waiting for a cold announcement to land in your inbox. Details at femtechlab.com.
1337 Ventures Alpha Startups Inno4Her: Southeast Asia's dedicated femtech program
This is the one program on the list built for a region first, ahead of stage or vertical. Inno4Her is an accelerator for femtech and women-led startups across Southeast Asia, filling a gap in the regional ecosystem. Founders building for underserved populations in the region don't have many comparable options, and that scarcity alone makes the program worth watching before you even get to what it offers.
Southeast Asia earns attention on its own economic merits, too. Growing healthcare demand is pushing the region into high-growth territory, the kind of market dynamic that tends to pull in capital once the infrastructure catches up. The program covers a range of femtech verticals and women-led startups, with a tent that stretches wider than femtech defined strictly. The tent stretches wider than "femtech" defined strictly.
Format-wise, it runs hybrid, blending in-person and virtual elements across the program duration. Check the program page for application requirements, since fee structures vary more across programs than most founders expect. Watch for the next cycle at 1337.ventures/inno4her.
Village Capital + Standard Chartered Foundation US Women in Tech Accelerator: watch for 2027 applications
This one isn't femtech-specific in the vertical sense, and there's no point stretching the label to pretend otherwise. It's a collaboration between Village Capital and Standard Chartered Foundation for women founders in tech broadly, and Young, as these programs go, even though the institutions behind it have been around for decades.
What you get: investment-readiness training and support designed to prepare founders for investor conversations. So why does a general tech program belong on a femtech list at all? Because of that same 4% figure from the opening section. Research from Village Capital and Standard Chartered Foundation jointly underpins the whole premise of the program. If you're a woman founder building a health or tech-enabled health business who needs investor-readiness training specifically, this fits, even without a strict clinical focus.
Watch vilcap.com/programs/women-in-tech-accelerator-us-2026 for the 2027 window to open.
Additional programs and funding sources worth tracking
A few more belong on a spreadsheet somewhere, even if they're earlier-stage or less settled right now. Flat6Labs operates out of the MENA region (flat6labs.com) and is worth checking for founders building in the Middle East and North Africa where dedicated infrastructure is still thin. Health Innovation Hub has an Accelerating FemTech program worth checking directly at healthinnovationhub.smapply.io to confirm current status before assuming it's live.
For founders who'd rather not give up equity at all, FundsForNGOs is worth checking for founders seeking non-dilutive support in global health contexts. And since VC covers only about 4% of total healthcare VC in women's health per VentureWell, federal non-dilutive funding through SBIR and STTR grants and NIH programs is often the more realistic first check for a device or diagnostic company still years from commercial revenue.
Two sub-trends worth watching if you're reading investor tea leaves. Menopause-focused VC grew 9% over three years, hitting $104 million in 2025 according to Dealroom, so founders in that specific niche are pulling more targeted attention than the category average gets. And per an SVB report from March 2026, AI-personalization companies in women's health are commanding valuations nearly triple those of their non-AI counterparts. That gap runs wide enough that it's worth flagging clearly in any accelerator application. If your product uses AI for personalization and your application doesn't say so in plain words, you're leaving a differentiator sitting on the table.
One practical note before moving on. Nearly every program above runs a waitlist before applications formally open, and joining early costs nothing. It just gets you the notification the moment the window opens instead of the demo day recap.
How to position your application across any of these programs
Stage fit comes first, and getting it wrong wastes the most founder time for the least good reason. Apply to Springboard, which targets late seed through Series B, while sitting at pre-seed, and you've burned a cycle you didn't need to burn. Same goes in reverse for FemTech Lab's early-stage cohort if you're already raising a Series B. Read the eligibility section twice before you write a single word of the application.
Framing carries just as much weight as fit does. The trend among selection committees, and the advice coming increasingly from femtech-focused investors, is to lead with market economics alongside the category label. A market worth close to $10 billion in 2026, growing at double digits a year, makes a business case on its own merits; "women's health is underserved" is also true and carries real weight of its own. Committees respond well when both show up together, especially when the human story underneath the numbers is easy to see.
Numbers help you calibrate your ask, too. The median femtech round sits at $6 million, while the average runs $17.9 million, per NewMarketPitch data covering July 2025 through June 2026. That gap between median and average tells you something specific: the distribution skews hard toward a handful of large raises, not spread evenly across the field. Another figure from the same source confirms it. The top 5 deals accounted for 74.65% of all disclosed femtech capital over the past 12 months. Capital concentration here runs real and steep, which is exactly why programs like Village Capital that build investment-readiness skills matter as much as they do. You're not just competing for interest; you're competing for a narrow band of attention that mostly goes to a small number of deals.
So what do selection committees actually look for once you've cleared the stage and framing bar? Clear clinical or commercial differentiation beyond the gender-health angle by itself. Evidence of founder-market fit, since lived experience carries real weight here and reviewers notice fast when it's missing. A specific, credible plan for reaching the next funding stage, given how tight the seed-to-Series-A bottleneck runs across the whole industry. And real fluency in the regulatory pathway relevant to your product, especially for a device or diagnostic where FDA clearance timelines shape everything downstream.
None of this requires reinventing your pitch from scratch. It requires a one-pager that's ready to go, a deck that's actually current, and a data room started before you need it, because these programs move from interview to decision faster than most founders expect. Scrambling to build materials after the callback is not a great way to make a first impression.
